- Home
- CAN vs CMPX Comparison
CAN vs CMPX Comparison
Compare CAN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- CMPX
- Stock Information
- Founded
- CAN 2013
- CMPX 2014
- Country
- CAN Singapore
- CMPX United States
- Employees
- CAN N/A
- CMPX N/A
- Industry
- CAN Semiconductors
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- CMPX Health Care
- Exchange
- CAN Nasdaq
- CMPX Nasdaq
- Market Cap
- CAN 384.3M
- CMPX 408.6M
- IPO Year
- CAN 2019
- CMPX N/A
- Fundamental
- Price
- CAN $0.91
- CMPX $1.99
- Analyst Decision
- CAN Strong Buy
- CMPX Strong Buy
- Analyst Count
- CAN 4
- CMPX 7
- Target Price
- CAN $3.88
- CMPX $12.43
- AVG Volume (30 Days)
- CAN 16.8M
- CMPX 824.3K
- Earning Date
- CAN 03-26-2025
- CMPX 05-12-2025
- Dividend Yield
- CAN N/A
- CMPX N/A
- EPS Growth
- CAN N/A
- CMPX N/A
- EPS
- CAN N/A
- CMPX N/A
- Revenue
- CAN $269,324,000.00
- CMPX $850,000.00
- Revenue This Year
- CAN $101.48
- CMPX $47.65
- Revenue Next Year
- CAN $44.75
- CMPX $3,552.43
- P/E Ratio
- CAN N/A
- CMPX N/A
- Revenue Growth
- CAN 27.35
- CMPX N/A
- 52 Week Low
- CAN $0.72
- CMPX $0.77
- 52 Week High
- CAN $3.27
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- CAN 32.01
- CMPX 32.35
- Support Level
- CAN $0.94
- CMPX $2.18
- Resistance Level
- CAN $1.10
- CMPX $2.41
- Average True Range (ATR)
- CAN 0.08
- CMPX 0.17
- MACD
- CAN 0.01
- CMPX -0.04
- Stochastic Oscillator
- CAN 16.20
- CMPX 2.86
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.